Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPN | P05981 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16167009 | 0.82 | MAPT (0.43) | POLBALDH1A1SCN2AMEN1MAPT | |
| SCHEMBL23296154 | 0.80 | DDB1 (0.57) | HPNPOLBALDH1A1SCN2APGR | |
| SCHEMBL3586307 | 0.72 | MAPT (0.56) | HPNPOLBALDH1A1SCN2AFGFR1 | |
| SCHEMBL5328812 | 0.71 | HPN (0.58) | HPNPOLBALDH1A1SCN2AMEN1 | |
| SCHEMBL10889569 | 0.70 | PDE4A (0.57) | HPNPOLBALDH1A1SCN2AFGFR1 | |
| SCHEMBL5249967 | 0.69 | PDE4A (0.57) | HPNSCN2AFGFR1MEN1MAPT | |
| SCHEMBL3970330 | 0.69 | ALDH1A1 (0.57) | HPNPOLBALDH1A1SCN2AFGFR1 | |
| SCHEMBL31739259 | 0.69 | ALDH1A1 (0.57) | HPNPOLBALDH1A1SCN2AFGFR1 | |
| SCHEMBL6772234 | 0.68 | CYP1A2 (0.43) | HPNPOLBALDH1A1SCN2AFGFR1 | |
| SCHEMBL30955769 | 0.68 | POLB (0.44) | POLBALDH1A1SCN2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015230-B1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | disclosed |
| US-6716838-B1 | INHIBITORS OF SERINE PROTEASES OF THE COAGULATION CASCADE | PHARMACIA CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6458952-B1 | ENZYME INHIBITORS FOR SERINE METHODS FOR PREVENTING AND TREATING THROMBOTIC CONDITIONS SUCH AS CORONARY ARTERY AND CEREBROVASCULAR DISEASE WITH COMPOUNDS THAT INHIBIT SERINE PROTEASES OF THE COAGULATION CASCADE. | PHARMACIA CORPORATION | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | TFPI, PLAT, PLAU | HPN 49/4885POLB 393/4885ALDH1A1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.